Beta-catenin inhibitors in cancer immunotherapy
US10753938B2 · kind B2 · utility
1Cited by
4References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 4, 2016 |
| Grant date | Aug 25, 2020 |
| Priority date | — |
| Expiry date | Aug 1, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70517
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compositions and methods for the treatment of cancer by inhibition of β-catenin or a β-catenin pathway. In particular, inhibitors of β-catenin and/or the Wnt/p-catenin signaling pathway are employed prevent or reverse evasion of immune response or immunotherapy by cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.